Preventing type 2 diabetes using combination therapy: Design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial

Diabetes, Obesity and Metabolism

Volumn 8, Issue 5, 2006, Pages 531-537

  Zinman, B ^a,b   Harris, S B ^c   Gerstein, H C ^d   Young, T K ^e   Raboud, J M ^f   Neuman, J ^a   Hanley, A J G ^a,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Diabetes prevention; Impaired glucose tolerance; Metformin; Rosiglitazone

Indexed keywords

GLUCOSE; METFORMIN; PLACEBO; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BEHAVIOR MODIFICATION; CANADA; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE COURSE; DOSE RESPONSE; DRUG CAPSULE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING;

EID: 33746878809     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00540.x     Document Type: Article

References (27)

1. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
2. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
3. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
4. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
5. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
6. DPP Research Group. The diabetes prevention program (DPP). Description of lifestyle intervention. Diabetes Care 2002; 25: 2165-2171.
7. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
8. DeFronzo RA. Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
9. Turner RC, Cull CA, Frighi V, Holmann RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
10. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
11. Charpentier G. Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 2002; 18: S70-S76.
12. Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of Type 2 diabetes. Diabetologia 2003; 46: M44-M50.
13. Fonseca V, Rosenstock J, Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000; 283: 1695-1702.
14. Alberti KGMM. The clinical implications of impaired glucose tolerance. Diabet Med 1996; 13: 927-937.
15. Unwin N, Shaw J, Zimmet P et al. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention. Diabet Med 2002; 19: 708-723.
16. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.
17. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003; 27: S10-S13.
18. Mathews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-2141.
20. Walker E, Mertz C, Kalten M, Flynn J. Risk perception for developing diabetes. Diabetes Care 2003; 26: 2543-2548.
21. Sakvig B. Diabetes prevention among First Nations school children in Sandy Lake Ontario: Evaluation of a culturally appropriate school-based nutrition and physical activity intervention. PhD Dissertation. John Hopkins School of Hygiene and Public Health 2002.
22. Diabetes Prevention Program Research Group. Prevention of Type 2 diabetes with troglitazone in the Diabetes Prevention Program (DPP). Diabetes 2003; 52: A58-A59.
23. Gerstein HC, Yusuf S, Holman R et al. The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial. Diabetologia 2004; 47: 1519-1527.
24. Bell DS. Beta-cell rejuvenation with thiazolidinediones. Am J Med 2003; 115: 20S-23S.
25. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
26. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108: 15S-22S.
27. Rosenstock J, Goldstein BJ, Wood-Dell MJ, Strow LJ, Waterhouse BR, Cobitz AR. Greater benefits of rosiglitazone added to submaximal dose of metformin compared to maximizing metformin dose in type 2 diabetes mellitus patients. Diabetes 2004; 53: A144.